{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:16:21Z","timestamp":1790252181784,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11904-025-00757-w","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T03:05:21Z","timestamp":1759719921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Current Tools to Diagnose and Predict Hepatocellular Carcinoma: Relevance to HIV and Hepatitis B Virus Coinfection"],"prefix":"10.1007","volume":"22","author":[{"given":"Edwin Wilbur","family":"Woodhouse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Hao","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Naggie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"issue":"12","key":"757_CR1","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1016\/S2352-3018(24)00212-1","volume":"11","author":"GH Collaborators","year":"2024","unstructured":"Collaborators GH. Global, regional, and national burden of HIV\/AIDS, 1990\u20132021, and forecasts to 2050, for 204 countries and territories: the global burden of disease study 2021. Lancet HIV. 2024;11(12):e807\u201322. https:\/\/doi.org\/10.1016\/S2352-3018(24)00212-1.","journal-title":"Lancet HIV"},{"issue":"9","key":"757_CR2","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","volume":"7","author":"Collaborators GBDHB","year":"2022","unstructured":"Collaborators GBDHB. Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796\u2013829. https:\/\/doi.org\/10.1016\/S2468-1253(22)00124-8.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"757_CR3","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","volume":"71","author":"S Leumi","year":"2020","unstructured":"Leumi S, Bigna JJ, Amougou MA, Ngouo A, Nyaga UF, Noubiap JJ. Global burden of hepatitis B infection in people living with human immunodeficiency virus: a systematic review and meta-analysis. Clin Infect Dis. 2020;71(11):2799\u2013806. https:\/\/doi.org\/10.1093\/cid\/ciz1170.","journal-title":"Clin Infect Dis"},{"issue":"9349","key":"757_CR4","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/s0140-6736(02)11913-1","volume":"360","author":"CL Thio","year":"2002","unstructured":"Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360(9349):1921\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(02)11913-1.","journal-title":"Lancet"},{"issue":"2","key":"757_CR5","doi-asserted-by":"publisher","first-page":"e2037512","DOI":"10.1001\/jamanetworkopen.2020.37512","volume":"4","author":"J Sun","year":"2021","unstructured":"Sun J, Althoff KN, Jing Y, Horberg MA, Buchacz K, Gill MJ, et al. Trends in hepatocellular carcinoma incidence and risk among persons with HIV in the US and Canada, 1996\u20132015. JAMA Netw Open. 2021;4(2):e2037512. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.37512.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"757_CR6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/hep.510290447","volume":"29","author":"JF Colin","year":"1999","unstructured":"Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29(4):1306\u201310. https:\/\/doi.org\/10.1002\/hep.510290447.","journal-title":"Hepatology"},{"key":"757_CR7","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv. Accessed Aug 5 2025."},{"issue":"2","key":"757_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1200\/JCO.2007.13.2043","volume":"26","author":"HL Chan","year":"2008","unstructured":"Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26(2):177\u201382. https:\/\/doi.org\/10.1200\/JCO.2007.13.2043.","journal-title":"J Clin Oncol"},{"issue":"1","key":"757_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58(1):98\u2013107. https:\/\/doi.org\/10.1002\/hep.26180.","journal-title":"Hepatology"},{"issue":"9865","key":"757_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468\u201375. https:\/\/doi.org\/10.1016\/S0140-6736(12)61425-1.","journal-title":"Lancet"},{"issue":"3","key":"757_CR11","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/hep.31839","volume":"74","author":"HN Kim","year":"2021","unstructured":"Kim HN, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, et al. Risk of HCC with hepatitis B viremia among HIV\/HBV-coinfected persons in North America. Hepatology. 2021;74(3):1190\u2013202. https:\/\/doi.org\/10.1002\/hep.31839.","journal-title":"Hepatology"},{"issue":"3","key":"757_CR12","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.31823","volume":"74","author":"RK Sterling","year":"2021","unstructured":"Sterling RK, King WC, Khalili M, Chung RT, Sulkowski M, Jain MK, et al. A prospective study evaluating changes in histology, clinical and virologic outcomes in HBV-HIV co-infected adults in North America. Hepatology. 2021;74(3):1174\u201389. https:\/\/doi.org\/10.1002\/hep.31823.","journal-title":"Hepatology"},{"issue":"7","key":"757_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/jnci\/djz214","volume":"112","author":"V Lo Re","year":"2020","unstructured":"Lo Re V, Justice AC, Taddei TH, Roy JA, Brown ST, Br\u00e4u N, et al. HIV RNA, CD4+ percentage, and risk of hepatocellular carcinoma by cirrhosis status. JNCI: J Natl Cancer Inst. 2020;112(7):747\u201355. https:\/\/doi.org\/10.1093\/jnci\/djz214.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"757_CR14","unstructured":"Prevention and management of hepatitis B virus infection in adults with HIV. 2022. https:\/\/www.hivguidelines.org\/guideline\/hiv-hbv\/. Accessed 10 Oct 2024."},{"key":"757_CR15","unstructured":"Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024."},{"issue":"2","key":"757_CR16","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","volume":"83","author":"European Association for the Study of the L","year":"2025","unstructured":"European Association for the Study of the L. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502\u201383. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018.","journal-title":"J Hepatol"},{"issue":"4","key":"757_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317\u201370. https:\/\/doi.org\/10.1007\/s12072-017-9799-9.","journal-title":"Hepatol Int"},{"issue":"6","key":"757_CR18","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. Aasld practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u201365. https:\/\/doi.org\/10.1097\/HEP.0000000000000466.","journal-title":"Hepatology"},{"key":"757_CR19","doi-asserted-by":"publisher","unstructured":"Cheraghpour M, Hatami B,Singal AG. Lifestyle and pharmacologic approaches to prevention of metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2025;23(5):685\u201394 e6. https:\/\/doi.org\/10.1016\/j.cgh.2024.09.041.","DOI":"10.1016\/j.cgh.2024.09.041"},{"issue":"1","key":"757_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"J Hepatol"},{"issue":"3","key":"757_CR21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.mayocpiqo.2019.04.005","volume":"3","author":"CT Frenette","year":"2019","unstructured":"Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A practical guideline for hepatocellular carcinoma screening in patients at risk. Mayo Clin Proc: Innov Qual Outcomes. 2019;3(3):302\u201310. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2019.04.005.","journal-title":"Mayo Clin Proc: Innov Qual Outcomes"},{"issue":"4","key":"757_CR22","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","volume":"64","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64(4):800\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.035.","journal-title":"J Hepatol"},{"issue":"5","key":"757_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jhep.2022.12.029","volume":"78","author":"B Surial","year":"2023","unstructured":"Surial B, Ramirez Mena A, Roumet M, Limacher A, Smit C, Leleux O, et al. External validation of the PAGE-B score for HCC risk prediction in people living with HIV\/HBV coinfection. J Hepatol. 2023;78(5):947\u201357. https:\/\/doi.org\/10.1016\/j.jhep.2022.12.029.","journal-title":"J Hepatol"},{"issue":"6","key":"757_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3748\/wjg.v28.i6.665","volume":"28","author":"P Gokcen","year":"2022","unstructured":"Gokcen P, Guzelbulut F, Adali G, Degirmenci Salturk AG, Ozturk O, Bahadir O, et al. Validation of the PAGE-B score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients on treatment. World J Gastroenterol. 2022;28(6):665\u201374. https:\/\/doi.org\/10.3748\/wjg.v28.i6.665.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"757_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/liv.14334","volume":"40","author":"T Voulgaris","year":"2020","unstructured":"Voulgaris T, Papatheodoridi M, Lampertico P, Papatheodoridis GV. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int. 2020;40(3):484\u201395. https:\/\/doi.org\/10.1111\/liv.14334.","journal-title":"Liver Int"},{"issue":"2","key":"757_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jhep.2019.03.032","volume":"71","author":"G Wandeler","year":"2019","unstructured":"Wandeler G, Mauron E, Atkinson A, Dufour JF, Kraus D, Reiss P, et al. Incidence of hepatocellular carcinoma in HIV\/HBV-coinfected patients on tenofovir therapy: relevance for screening strategies. J Hepatol. 2019;71(2):274\u201380. https:\/\/doi.org\/10.1016\/j.jhep.2019.03.032.","journal-title":"J Hepatol"},{"key":"757_CR27","doi-asserted-by":"publisher","unstructured":"Sparchez Z, Craciun R, Caraiani C, Horhat A, Nenu I, Procopet B, et al. Ultrasound or sectional imaging techniques as screening tools for hepatocellular carcinoma: fall forward or move forward? J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10050903.","DOI":"10.3390\/jcm10050903"},{"issue":"3","key":"757_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/hep.32185","volume":"75","author":"AG Singal","year":"2022","unstructured":"Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, et al. Galad demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022;75(3):541\u20139. https:\/\/doi.org\/10.1002\/hep.32185.","journal-title":"Hepatology"},{"issue":"15","key":"757_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13152484","volume":"13","author":"X Yu","year":"2023","unstructured":"Yu X, Lei X. Application of the multi-omics liquid biopsy method M2P-HCC in early liver cancer screening for high-risk individuals with hepatitis B-related liver cancer. Diagnostics. 2023;13(15):2484. https:\/\/doi.org\/10.3390\/diagnostics13152484.","journal-title":"Diagnostics"},{"issue":"6","key":"757_CR30","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","volume":"154","author":"K Tzartzeva","year":"2018","unstructured":"Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154(6):1706-18 e1. https:\/\/doi.org\/10.1053\/j.gastro.2018.01.064.","journal-title":"Gastroenterology"},{"issue":"1","key":"757_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hep.29487","volume":"67","author":"LR Roberts","year":"2018","unstructured":"Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology. 2018;67(1):401\u201321. https:\/\/doi.org\/10.1002\/hep.29487.","journal-title":"Hepatology"},{"key":"757_CR32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2342-8-5","volume":"8","author":"MO Obajimi","year":"2008","unstructured":"Obajimi MO, Atalabi MO, Ogbole GI, Adeniji-Sofoluwe AT, Agunloye AM, Adekanmi AJ, et al. Abdominal ultrasonography in HIV\/AIDS patients in southwestern Nigeria. BMC Med Imaging. 2008;8:5. https:\/\/doi.org\/10.1186\/1471-2342-8-5.","journal-title":"BMC Med Imaging"},{"issue":"2","key":"757_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/QAD.0000000000002065","volume":"33","author":"N Merchante","year":"2019","unstructured":"Merchante N, Figueruela B, Rodriguez-Fernandez M, Rodriguez-Arrondo F, Revollo B, Ibarra S, et al. Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients. AIDS. 2019;33(2):269\u201378. https:\/\/doi.org\/10.1097\/QAD.0000000000002065.","journal-title":"AIDS"},{"issue":"6","key":"757_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/cld.923","volume":"16","author":"Y Chang","year":"2020","unstructured":"Chang Y, Lee JH. Optimal modalities for HCC surveillance in a high-incidence region. Clin Liver Dis. 2020;16(6):236\u20139. https:\/\/doi.org\/10.1002\/cld.923.","journal-title":"Clin Liver Dis"},{"issue":"6","key":"757_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/14737140.2022.2074404","volume":"22","author":"J Melendez-Torres","year":"2022","unstructured":"Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther. 2022;22(6):621\u201332. https:\/\/doi.org\/10.1080\/14737140.2022.2074404.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"757_CR36","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jhep.2021.01.041","volume":"75","author":"P Gupta","year":"2021","unstructured":"Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J Hepatol. 2021;75(1):108\u201319. https:\/\/doi.org\/10.1016\/j.jhep.2021.01.041.","journal-title":"J Hepatol"},{"key":"757_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1415859","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang L, Fatemi M, Alizad A. Artificial intelligence techniques in liver cancer. Front Oncol. 2024;14:1415859. https:\/\/doi.org\/10.3389\/fonc.2024.1415859.","journal-title":"Front Oncol"},{"issue":"2","key":"757_CR38","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/hep.31309","volume":"73","author":"E Wolf","year":"2021","unstructured":"Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. Hepatology. 2021;73(2):713\u201325. https:\/\/doi.org\/10.1002\/hep.31309.","journal-title":"Hepatology"},{"issue":"9","key":"757_CR39","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1007\/s10620-014-3142-2","volume":"59","author":"M Sarkar","year":"2014","unstructured":"Sarkar M, Shvachko VA, Ready JB, Pauly MP, Terrault NA, Peters MG, et al. Characteristics and management of patients with chronic hepatitis B in an integrated care setting. Dig Dis Sci. 2014;59(9):2100\u20138. https:\/\/doi.org\/10.1007\/s10620-014-3142-2.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"757_CR40","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/cid\/ciac227","volume":"75","author":"TH Lee","year":"2022","unstructured":"Lee TH, Hunt CM, Maier MM, Lowy E, Beste LA. Hepatitis B virus-related care quality in patients with hepatitis B\/human immunodeficiency virus coinfection versus hepatitis B monoinfection: a national cohort study. Clin Infect Dis. 2022;75(9):1529\u201336. https:\/\/doi.org\/10.1093\/cid\/ciac227.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 3","key":"757_CR41","first-page":"A66","volume":"73","author":"HBR MacCarthy","year":"2024","unstructured":"MacCarthy HBR, B\u00f6hning D, et al. Who doesn\u2019t turn up? Exploring patient characteristics associated with non-attendance with regular hepatocellular carcinoma surveillance: a systematic review and meta-analysis. Gut. 2024;73(Suppl 3):A66.","journal-title":"Gut"},{"key":"757_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00171","volume":"10","author":"P Dasgupta","year":"2020","unstructured":"Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, Baade PD. Global trends in incidence rates of primary adult liver cancers: a systematic review and meta-analysis. Front Oncol. 2020;10:171. https:\/\/doi.org\/10.3389\/fonc.2020.00171.","journal-title":"Front Oncol"},{"key":"757_CR43","doi-asserted-by":"publisher","unstructured":"Sun R, Wang X, Ma J, Cai Y, Li L, Wang S. The roles and clinical significance of major hepatic-derived metabolites in hepatocellular carcinoma. J Gastroenterol Hepatol. 2025. https:\/\/doi.org\/10.1111\/jgh.70008.","DOI":"10.1111\/jgh.70008"},{"issue":"2","key":"757_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3748\/wjg.v28.i2.216","volume":"28","author":"H Hanif","year":"2022","unstructured":"Hanif H, Ali MJ, Susheela AT, Khan IW, Luna-Cuadros MA, Khan MM, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022;28(2):216\u201329. https:\/\/doi.org\/10.3748\/wjg.v28.i2.216.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"757_CR45","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/jvh.13388","volume":"28","author":"X Qian","year":"2021","unstructured":"Qian X, Liu S, Long H, Zhang S, Yan X, Yao M, et al. Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy. J Viral Hepat. 2021;28(1):20\u20139. https:\/\/doi.org\/10.1111\/jvh.13388.","journal-title":"J Viral Hepat"},{"issue":"8","key":"757_CR46","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3390\/v14081669","volume":"14","author":"X Qian","year":"2022","unstructured":"Qian X, Liu Y, Wu F, Zhang S, Gong J, Nan Y, et al. The performance of serum alpha-fetoprotein for detecting early-stage hepatocellular carcinoma is influenced by antiviral therapy and serum aspartate aminotransferase: a study in a large cohort of hepatitis B virus-infected patients. Viruses. 2022;14(8):1669. https:\/\/doi.org\/10.3390\/v14081669.","journal-title":"Viruses"},{"issue":"5","key":"757_CR47","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.cgh.2013.09.053","volume":"12","author":"P Gopal","year":"2014","unstructured":"Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, et al. Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12(5):870\u20137. https:\/\/doi.org\/10.1016\/j.cgh.2013.09.053.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"757_CR48","doi-asserted-by":"publisher","first-page":"366","DOI":"10.37349\/etat.2023.00140","volume":"4","author":"MLS Silva","year":"2023","unstructured":"Silva MLS. Capitalizing glycomic changes for improved biomarker-based cancer diagnostics. Explor Target Antitumor Ther. 2023;4(3):366\u201395. https:\/\/doi.org\/10.37349\/etat.2023.00140.","journal-title":"Explor Target Antitumor Ther"},{"issue":"4","key":"757_CR49","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3390\/v14040775","volume":"14","author":"M Force","year":"2022","unstructured":"Force M, Park G, Chalikonda D, Roth C, Cohen M, Halegoua-DeMarzio D, et al. Alpha-fetoprotein (AFP) and AFP-L3 is most useful in detection of recurrence of hepatocellular carcinoma in patients after tumor ablation and with low AFP level. Viruses. 2022;14(4):775. https:\/\/doi.org\/10.3390\/v14040775.","journal-title":"Viruses"},{"key":"757_CR50","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519889270","author":"T Song","year":"2019","unstructured":"Song T, Wang L, Su B, Zeng W, Jiang T, Zhang T, et al. Diagnostic value of alpha-fetoprotein, lens culinaris agglutinin-reactive alpha-fetoprotein, and des-gamma-carboxyprothrombin in hepatitis B virus-related hepatocellular carcinoma. J Int Med Res. 2019. https:\/\/doi.org\/10.1177\/0300060519889270.","journal-title":"J Int Med Res"},{"issue":"5","key":"757_CR51","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1002\/hep.30233","volume":"69","author":"J Choi","year":"2019","unstructured":"Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology. 2019;69(5):1983\u201394. https:\/\/doi.org\/10.1002\/hep.30233.","journal-title":"Hepatology"},{"issue":"3","key":"757_CR52","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1158\/1055-9965.EPI-18-0281","volume":"28","author":"JD Yang","year":"2019","unstructured":"Yang JD, Addissie BD, Mara KC, Harmsen WS, Dai J, Zhang N, et al. Galad score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of galadus score. Cancer Epidemiol Biomarkers Prev. 2019;28(3):531\u20138. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0281.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"757_CR53","doi-asserted-by":"publisher","first-page":"e0282539","DOI":"10.1371\/journal.pone.0282539","volume":"18","author":"PM Davwar","year":"2023","unstructured":"Davwar PM, Okeke E, Duguru M, Nyam D, Bell K, Odeghe EA, et al. Hepatocellular carcinoma presentation and prognosis among Nigerian adults with and without HIV. PLoS One. 2023;18(3):e0282539. https:\/\/doi.org\/10.1371\/journal.pone.0282539.","journal-title":"PLoS One"},{"issue":"8","key":"757_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ph14080735","volume":"14","author":"C Schotten","year":"2021","unstructured":"Schotten C, Ostertag B, Sowa JP, Manka P, Bechmann LP, Hilgard G, et al. GALAD score detects early-stage hepatocellular carcinoma in a European cohort of chronic hepatitis B and C patients. Pharmaceuticals (Basel). 2021;14(8):735. https:\/\/doi.org\/10.3390\/ph14080735.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"757_CR55","doi-asserted-by":"publisher","first-page":"167","DOI":"10.17998\/jlc.2022.09.19","volume":"22","author":"Y Chang","year":"2022","unstructured":"Chang Y, Jeong SW, Jang JY, Eun H, Lee YS, Song DS, et al. The diagnostic value of circulating tumor DNA in hepatitis B virus induced hepatocellular carcinoma: a systematic review and meta-analysis. J Liver Cancer. 2022;22(2):167\u201377. https:\/\/doi.org\/10.17998\/jlc.2022.09.19.","journal-title":"J Liver Cancer"},{"issue":"1","key":"757_CR56","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/cid\/cix747","volume":"66","author":"G-M Kouam\u00e9","year":"2018","unstructured":"Kouam\u00e9 G-M, Boyd A, Moh R, Badje A, Gabillard D, Ouattara E, et al. Higher mortality despite early antiretroviral therapy in human immunodeficiency virus and hepatitis B virus (HBV)\u2013coinfected patients with high HBV replication. Clin Infect Dis. 2018;66(1):112\u201320. https:\/\/doi.org\/10.1093\/cid\/cix747.","journal-title":"Clin Infect Dis"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00757-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-025-00757-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-025-00757-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T14:03:25Z","timestamp":1769609005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-025-00757-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1007\/s11904-025-00757-w","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"EWW and THL declare no conflict of interest. SN reports grants from the NIH during the conduct of the study as well as grants from Gilead; non-financial support from Pardes Biosciences, Scientific Advisor, non-financial support from Silverback Therapeutics Scientific Advisor, and Vir Biotechnology Scientific Advisor stocks owned, and non-financial support from Personal Health Insights DSMB; and personal fees from BMS\/PRA Health Sciences Event Adjudication outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"47"}}